GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Medpace Holdings Inc (NAS:MEDP) » Definitions » Beneish M-Score

Medpace Holdings (Medpace Holdings) Beneish M-Score : -2.89 (As of May. 01, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Medpace Holdings Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.89 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Medpace Holdings's Beneish M-Score or its related term are showing as below:

MEDP' s Beneish M-Score Range Over the Past 10 Years
Min: -3.04   Med: -2.71   Max: -2.09
Current: -2.89

During the past 11 years, the highest Beneish M-Score of Medpace Holdings was -2.09. The lowest was -3.04. And the median was -2.71.


Medpace Holdings Beneish M-Score Historical Data

The historical data trend for Medpace Holdings's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medpace Holdings Beneish M-Score Chart

Medpace Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.62 -2.85 -2.59 -2.81 -2.73

Medpace Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.04 -2.73 -2.71 -2.73 -2.89

Competitive Comparison of Medpace Holdings's Beneish M-Score

For the Diagnostics & Research subindustry, Medpace Holdings's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medpace Holdings's Beneish M-Score Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Medpace Holdings's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Medpace Holdings's Beneish M-Score falls into.



Medpace Holdings Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Medpace Holdings for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.8626+0.528 * 1.0603+0.404 * 0.7998+0.892 * 1.2557+0.115 * 0.8612
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9519+4.679 * -0.109545-0.327 * 0.829
=-2.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was $279 Mil.
Revenue was 511.044 + 498.401 + 492.499 + 460.868 = $1,963 Mil.
Gross Profit was 155.142 + 136.806 + 133.193 + 124.317 = $549 Mil.
Total Current Assets was $745 Mil.
Total Assets was $1,796 Mil.
Property, Plant and Equipment(Net PPE) was $257 Mil.
Depreciation, Depletion and Amortization(DDA) was $27 Mil.
Selling, General, & Admin. Expense(SGA) was $167 Mil.
Total Current Liabilities was $957 Mil.
Long-Term Debt & Capital Lease Obligation was $136 Mil.
Net Income was 102.591 + 78.298 + 70.55 + 61.068 = $313 Mil.
Non Operating Income was 4.593 + 1.543 + -1.602 + -1.283 = $3 Mil.
Cash Flow from Operations was 152.677 + 156.395 + 114.385 + 82.518 = $506 Mil.
Total Receivables was $258 Mil.
Revenue was 434.074 + 394.098 + 383.744 + 351.207 = $1,563 Mil.
Gross Profit was 130.189 + 115.731 + 119.034 + 98.996 = $464 Mil.
Total Current Assets was $368 Mil.
Total Assets was $1,396 Mil.
Property, Plant and Equipment(Net PPE) was $257 Mil.
Depreciation, Depletion and Amortization(DDA) was $23 Mil.
Selling, General, & Admin. Expense(SGA) was $140 Mil.
Total Current Liabilities was $882 Mil.
Long-Term Debt & Capital Lease Obligation was $143 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(279.166 / 1962.812) / (257.746 / 1563.123)
=0.142228 / 0.164892
=0.8626

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(463.95 / 1563.123) / (549.458 / 1962.812)
=0.29681 / 0.279934
=1.0603

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (744.902 + 257.403) / 1795.789) / (1 - (367.622 + 257.064) / 1395.723)
=0.441858 / 0.552428
=0.7998

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1962.812 / 1563.123
=1.2557

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(23.191 / (23.191 + 257.064)) / (27.362 / (27.362 + 257.403))
=0.08275 / 0.096086
=0.8612

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(167.406 / 1962.812) / (140.061 / 1563.123)
=0.085289 / 0.089603
=0.9519

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((136.156 + 956.645) / 1795.789) / ((142.689 + 881.889) / 1395.723)
=0.608535 / 0.734084
=0.829

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(312.507 - 3.251 - 505.975) / 1795.789
=-0.109545

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Medpace Holdings has a M-score of -2.89 suggests that the company is unlikely to be a manipulator.


Medpace Holdings Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Medpace Holdings's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Medpace Holdings (Medpace Holdings) Business Description

Traded in Other Exchanges
Address
5375 Medpace Way, Cincinnati, OH, USA, 45227
Medpace is a late-stage contract research organization, or CRO, that provides full-service drug development and clinical trial services to small and midsized biotechnology, pharmaceutical, and medical device firms. Medpace also offers ancillary services such as bio-analytical laboratory services and imaging capabilities. The company was founded over 30 years ago, and it has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are principally based in the U.S., but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in February 2014, and it exited Medpace in August 2018.
Executives
Susan E Burwig officer: Exec. VP, Operations C/O MEDPACE HOLDINGS, INC., 5375 MEDPACE WAY, CINCINNATI OH 45227
August J. Troendle director, 10 percent owner, officer: CEO 5375 MEDPACE WAY, CINCINNATI OH 45227
Medpace Investors, Llc 10 percent owner 4620 WESLEY AVENUE, CINCINNATI OH 45212
Robert O. Kraft director ONE CVS DRIVE, WOONSOCKET RI 02895
Kevin M. Brady officer: CFO & Treasurer MEDPACE HOLDINGS, INC., 5375 MEDPACE WAY, CINCINNATI OH 45227
Stephen P Ewald officer: General Counsel & Corp. Secy. C/O MEDPACE HOLDINGS,INC., 5375 MEDPACE WAY, CINTINNATI OH 45227
Femida H. Gwadry-sridhar director 5375 MEDPACE WAY, CINCINNATI OH 45227
Ashley M. Keating director 5375 MEDPACE WAY, CINCINNATI OH 45227
Davenport Fred B Jr director
Brian T Carley director C/O MEDPACE HOLDINGS, INC., 5375 MEDPACE WAY, CINCINNATI OH 45227
Mccarthy Cornelius P. Iii director 5375 MEDPACE WAY, CINCINNATI OH 45227
Jesse J Geiger officer: CFO & COO, Lab Operations C/O MEDPACE HOLDINGS, INC., 5375 MEDPACE WAY, CINCINNATI OH 45227
Tom C King director 5375 MEDPACE WAY, CINCINNATI OH 45227
Medpace Limited Partnership 10 percent owner EAST WING, TRAFALGAR COURT, LES BANQUES, ST. PETER PORT, CHANNEL ISLANDS Y7 GY1 3PP
Cinven Capital Management (v) General Partner Ltd 10 percent owner EAST WING, TRAFALGAR COURT, LES BANQUES, ST. PETER PORT Y7 GY1 3PP